Readoutin 75d
Innovent Biologics (Suzhou) Co. Ltd. — Aflibercept Ophthalmic
Phase 3 primary completion: A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD.
- Date
- Feb 2027
- Type
- Readout
- Indication
- Neovascular Age-related Macular Degeneration